Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 18 Kidney Neoplasms 2 Urogenital Neoplasms 1 Thrombocytopenia 1 Renal Insufficiency 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Metastatic Hormone Naive Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Metastatic Castration Resistant Prostate Cancer 1 Liver Neoplasms 1 High-Risk Localized Prostate Cancer 1 Genital Neoplasms, Male 1 Cytopenia 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Anemia 1

Interventions

Oxaliplatin 67 Capecitabine 60 Fluorouracil 58 Bevacizumab 54 Gemcitabine 51 Paclitaxel 50 Leucovorin 50 Irinotecan 40 Docetaxel 39 Carboplatin 39 Cisplatin 38 pembrolizumab 37 Nivolumab 37 Cetuximab 35 Sunitinib 25 Trastuzumab 24 Radiosurgery 24 Radiotherapy 21 Doxorubicin 21 Cyclophosphamide 21 Panitumumab 20 Drug Therapy 19 Pemetrexed 18 Everolimus 18 Sorafenib 17 Interleukin-2 16 Fulvestrant 16 Albumin-Bound Paclitaxel 16 atezolizumab 15 Erlotinib Hydrochloride 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasm Metastasis × Pluvicto × Clear all

NCT03392428 2022-06-13

TheraP

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Completed

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡